Clinical Trials Directory

This study has two groups based on a test called the Signatera test. People in Group A have a positive test. They will be placed by chance into one of two treatment groups. One group will get a medicine called nivolumab. The other group will get two medicines, nivolumab and relatlimab. These medicines are given through a vein once every 28 days, and people can get up to 12 cycles. People in Group B have a negative test. They will be placed by chance into one of two choices. One choice is to get nivolumab right away, given through a vein once every 28 days for up to 12 cycles. The other choice is close monitoring without starting medicine right away. If their Signatera test changes from negative to positive, they will then be offered nivolumab for up to 12 cycles.

This study has two groups. In the first group, people take a usual cancer medicine called zanubrutinib. It is taken as a pill by mouth two times each day, and the treatment is given in cycles that last 28 days. In the second group, people take zanubrutinib first for a few cycles. After that, they also start taking a new study medicine called sonrotoclax. This medicine is added slowly, starting at a low dose and increasing step by step each week until the full dose is reached. This is done to help keep people safe and lower the risk of side effects. The study compares these two treatment plans to see if adding the new medicine works better than the usual treatment alone.

The ALPINE study wants to find out if a medicine called brepocitinib can help control a condition called lichen planopilaris. The medicine is a pill that people take once each day. The study will also compare how well the medicine works when compared to a placebo, which is a pill that has no medicine in it.

In this study, you will take a medicine called ALTA3263 by mouth every day. You will keep taking it until your cancer gets worse or until you need to stop because of strong or frequent side effects. While you are in the study, you will go to the clinic for regular visits. During these visits, the study team will do tests to check your health and collect information for research.

We are doing this study to find out if an experimental drug called ALXN2030 (the study drug) is a safe and effective option for people diagnosed with antibody-mediated rejection (AMR) of a transplanted kidney.

We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.